Form 4: Cidara Therapeutics Director Acquires Stock Options Under RA Capital Arrangement

Director Laura Tadvalkar acquired stock options in Cidara Therapeutics, holding them for the benefit of RA Capital Healthcare Fund.

Summary

• Laura Tadvalkar, a director of Cidara Therapeutics, acquired stock options on July 18, 2024.
• The options, priced at $12.64, grant the right to buy 2,125 shares of common stock.
• The options vest on the earlier of the first anniversary of the grant date or the day prior to the Issuer's 2025 annual meeting of stockholders.
• Tadvalkar holds the options for the benefit of RA Capital Healthcare Fund, L.P., under an arrangement with RA Capital Management, L.P.
• She disclaims beneficial ownership of the options and underlying common stock, as any proceeds from exercising the options will offset advisory fees owed by the Fund to the Adviser.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing a stock option grant. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, transact in their company's stock, providing transparency to investors.

Related Party Transactions

• The Reporting Person's arrangement with RA Capital Management, L.P. (the 'Adviser'), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the 'Fund').
• The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund to the Adviser.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider activity.
• The arrangement with RA Capital may indirectly benefit the Fund's investors.

Key Dates